Tagged with MSD

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Rankings The top 10 of Pharmaceutical Exec’s Top 50 Companies 2020. Roche overtakes Pfizer to take the number one spot, followed by Novartis which moves up from third to second on the list. For the full list and extensive analysis, see the Pharma Exec website here.   Made with Visme Infographic Maker

Vaccines Vaccines are back on top of the pharma priority list as companies race against the clock to develop the first effective COVID-19 vaccine. Below we present the top 10 pharma companies producing vaccines globally, based on revenues from 2017 and projected revenues from 2024. GSK leads the pack with over…

Coronavirus During the 30 April IFPMA virtual media briefing on COVID-19 treatments, key global executives pushed beyond catchy headlines to discuss the current reality of COVID-19 R&D efforts.   MSD (Merck & Co. in the US and Canada) executive vice president and chief patient officer Julie Gerberding drew upon her valuable…

Global The world’s bestselling treatments for 2019 by sales in USD billions. AbbVie’s Humira is out in front with USD 19.7 billion in sales, followed by Bristol Myers Squibb’s Eliquis, and Merck & Co. (MSD globally)’s Keytruda.   Made with Visme Infographic Maker

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Morocco Alain Barry, managing director of MSD in Morocco, shares how the organization is partnering with the Moroccan healthcare community to ensure that patients have access to innovative therapies and vaccines.   Morocco has been a pioneer in the region in the field of immunization by introducing innovative vaccines in the…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

Belgium Luxembourg Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home to the company’s Heist-op-den-Berg production facility, a key manufacturing site for the global group. Vanneste delivers a strong message about…